NASDAQ:MCRB - Seres Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.13 -0.18 (-4.18 %) (As of 05/20/2019 08:30 AM ET)Previous Close$4.31Today's Range$4.06 - $4.3352-Week Range$4.04 - $9.75Volume142,876 shsAverage Volume211,371 shsMarket Capitalization$169.74 millionP/E RatioN/ADividend YieldN/ABeta1.8 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study in patients with active mild-to-moderate ulcerative colitis; and SER-401, which is in Phase Ib study in metastatic melanoma to augment the efficacy of anti-PD-1 immunotherapy. In addition, the company engages in the development of SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-109, a donor-derived purified bacterial spore-based microbiome therapeutic candidate that is in Phase III clinical trial to correct dysbiosis in the colonic microbiome in the setting of recurrent CDI. Further, it is developing SER-262, a multi-strain Ecobiotic microbiome therapeutic candidate, which is in Phase Ib study for CDI antibiotic treatment; and SER-155, a microbiome therapeutic candidate to correct dysbiosis in patients following allogeneic hematopoietic stem cell or solid organ transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Receive MCRB News and Ratings via Email Sign-up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MCRB Previous Symbol CUSIPN/A CIK1609809 Webwww.serestherapeutics.com Phone617-945-9626Debt Debt-to-Equity RatioN/A Current Ratio1.63 Quick Ratio1.63Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$28.27 million Price / Sales6.00 Cash FlowN/A Price / Cash FlowN/A Book Value($1.70) per share Price / Book-2.43Profitability EPS (Most Recent Fiscal Year)($2.43) Net Income$-98,940,000.00 Net Margins-301.60% Return on Equity-1,583.95% Return on Assets-79.97%Miscellaneous Employees145 Outstanding Shares41,100,000Market Cap$169.74 million Next Earnings Date8/1/2019 (Estimated) OptionableOptionable Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions What is Seres Therapeutics' stock symbol? Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB." How were Seres Therapeutics' earnings last quarter? Seres Therapeutics Inc (NASDAQ:MCRB) announced its quarterly earnings results on Thursday, May, 2nd. The biotechnology company reported ($0.55) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.12. The biotechnology company had revenue of $7.32 million for the quarter, compared to analyst estimates of $8.61 million. Seres Therapeutics had a negative return on equity of 1,583.95% and a negative net margin of 301.60%. View Seres Therapeutics' Earnings History. When is Seres Therapeutics' next earnings date? Seres Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Seres Therapeutics. What price target have analysts set for MCRB? 7 analysts have issued twelve-month target prices for Seres Therapeutics' shares. Their predictions range from $7.00 to $16.00. On average, they anticipate Seres Therapeutics' share price to reach $12.20 in the next twelve months. This suggests a possible upside of 195.4% from the stock's current price. View Analyst Price Targets for Seres Therapeutics. What is the consensus analysts' recommendation for Seres Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seres Therapeutics. What are Wall Street analysts saying about Seres Therapeutics stock? Here are some recent quotes from research analysts about Seres Therapeutics stock: 1. According to Zacks Investment Research, "Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (5/9/2019) 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $13 price target. We believe Seres is at the forefront of unlocking the potential for microbiome modulation to generate novel methods by which to treat medical conditions. Continuing with the company’s re-prioritization, Seres announced modifications to the ongoing SER-109 Phase 3 trial to potentially accelerate the top-line data readout. We believe recovery of the stock could be supported by this and the other recent changes that may expedite data demonstrating that microbiome-based therapies have their desired effects." (5/7/2019) 3. HC Wainwright analysts commented, "We reiterate our Buy rating with an $8 PT, which was derived by discounting free cash flows for each year by 25%, dividing them by our projected number of shares for each year to account for the effects of share dilution, using a 2% terminal growth rate, and a 72% probability-of-success." (5/3/2019) Has Seres Therapeutics been receiving favorable news coverage? News headlines about MCRB stock have been trending positive this week, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Seres Therapeutics earned a daily sentiment score of 2.3 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. Who are some of Seres Therapeutics' key competitors? Some companies that are related to Seres Therapeutics include Emisphere Technologies (EMIS), Lexicon Pharmaceuticals (LXRX), Akebia Therapeutics (AKBA), Advanz Pharma (CXRXF), Puma Biotechnology (PBYI), Organogenesis (ORGO), Stemline Therapeutics (STML), Crinetics Pharmaceuticals (CRNX), CannTrust (CTST), Kura Oncology (KURA), ZEALAND PHARMA/S (ZEAL), TG Therapeutics (TGTX), Aurinia Pharmaceuticals (AUPH), Viking Therapeutics (VKTX) and Cytokinetics (CYTK). What other stocks do shareholders of Seres Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include Opko Health (OPK), Juno Therapeutics (JUNO), TherapeuticsMD (TXMD), Walt Disney (DIS), Synergy Pharmaceuticals (SGYP), Anavex Life Sciences (AVXL), Novavax (NVAX), Progenics Pharmaceuticals (PGNX), Sangamo Therapeutics (SGMO) and Verastem (VSTM). Who are Seres Therapeutics' key executives? Seres Therapeutics' management team includes the folowing people: Mr. Eric D. Shaff, Pres, CEO & Director (Age 43)Mr. Marcus Chapman, VP of Fin., Principal Financial & Accounting Officer (Age 48)Dr. John G. Aunins, CTO and Exec. VP of Bioprocess & Manufacturing (Age 58)Dr. Matthew R. Henn, Exec. VP & Chief Scientific Officer (Age 44)Mr. Carlo Tanzi, VP of Investor Relations & Corp. Communications When did Seres Therapeutics IPO? (MCRB) raised $101 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers. Who are Seres Therapeutics' major shareholders? Seres Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (14.17%), ARK Investment Management LLC (12.87%), BlackRock Inc. (5.35%), Renaissance Technologies LLC (2.20%), Nikko Asset Management Americas Inc. (1.99%) and Sumitomo Mitsui Trust Holdings Inc. (1.95%). Company insiders that own Seres Therapeutics stock include David N Cook, Eric D Shaff, John G Aunins, Roger Pomerantz and Thomas Desrosier. View Institutional Ownership Trends for Seres Therapeutics. Which major investors are selling Seres Therapeutics stock? MCRB stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc. and Lakeview Capital Partners LLC. Company insiders that have sold Seres Therapeutics company stock in the last year include Eric D Shaff, John G Aunins, Roger Pomerantz and Thomas Desrosier. View Insider Buying and Selling for Seres Therapeutics. Which major investors are buying Seres Therapeutics stock? MCRB stock was bought by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., JPMorgan Chase & Co., Marshall Wace LLP, Morgan Stanley, Renaissance Technologies LLC and Alpine Woods Capital Investors LLC. View Insider Buying and Selling for Seres Therapeutics. How do I buy shares of Seres Therapeutics? Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Seres Therapeutics' stock price today? One share of MCRB stock can currently be purchased for approximately $4.13. How big of a company is Seres Therapeutics? Seres Therapeutics has a market capitalization of $169.74 million and generates $28.27 million in revenue each year. The biotechnology company earns $-98,940,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis. Seres Therapeutics employs 145 workers across the globe. What is Seres Therapeutics' official website? The official website for Seres Therapeutics is http://www.serestherapeutics.com. How can I contact Seres Therapeutics? Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626 or via email at [email protected] MarketBeat Community Rating for Seres Therapeutics (NASDAQ MCRB)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 333 (Vote Outperform)Underperform Votes: 260 (Vote Underperform)Total Votes: 593MarketBeat's community ratings are surveys of what our community members think about Seres Therapeutics and other stocks. Vote "Outperform" if you believe MCRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MCRB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: Compound Interest and Why It Matters When Investing Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.